Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease

Journal of Neurochemistry

Volumn 107, Issue 1, 2008, Pages 141-151

  Park, Hyun Jung ^a   Lee, Phil Hyu ^b   Bang, Oh Young ^c   Lee, Gwang ^a   Ahn, Young Hwan ^a  

^a Ajou University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Mesenchymal stem cell; Neuroprotection; Parkinson's disease

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3;

ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; CASPASE 3; CELL COMMUNICATION; CELL COUNT; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; CYSTEINE PROTEINASE INHIBITORS; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; LEUPEPTINS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; NERVE GROWTH FACTORS; NEURONS; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TREATMENT OUTCOME; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; RATTUS;

EID: 51849088599     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05589.x     Document Type: Article

References (50)

1. Adler C. H. (2005) Nonmotor complications in Parkinson's disease. Mov. Disord. 20 (Suppl. 11 S23 S29.
2. Aubin N., Curet O., Deffois A. Carter C. (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem. 71, 1635 1642.
3. Bang O. Y., Lee J. S., Lee P. H. Lee G. (2005) Autologous mesenchymal stem cell transplantation in stroke patients. Ann. Neurol. 57, 874 882.
4. Banisadr G., Skrzydelski D., Kitabgi P., Rostène W. Parsadaniantz S. M. (2003) Highly regionalized distribution of stromal cell-derived factor-1/CXCL12 in adult rat brain: constitutive expression in cholinergic, dopaminergic and vasopressinergic neurons. Eur. J. Neurosci. 18, 1593 1606.
5. Barzilay R., Kan I., Ben-Zur T., Bulvik S., Melamed E. Offen D. (2008) Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols. Stem Cells Dev. doi :.
6. Beal F. Lang A. (2006) The proteasomal inhibition model of Parkinson's disease: 'boon or bust'? Ann. Neurol. 60, 158 161.
7. Blondheim N. R., Levy Y. S., Ben-Zur T. et al. (2006) Human mesenchymal stem cells express neural genes, suggesting a neural predisposition. Stem Cells Dev 15, 141 164.
8. Bove J., Zhou C., Jackson-Lewis V., Taylor J., Chu Y., Rideout H. J., Wu D. C., Kordower J. H., Petrucelli L. Przedborski S. (2006) Proteasome inhibition and Parkinson's disease modeling. Ann. Neurol. 60, 260 264.
9. Caplan A. I. Dennis J. E. (2006) Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 98, 1076 1084.
10. Chamberlain G., Fox J., Ashton B. Middleton J. (2007) Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25, 2739 2749.
11. Chen H., Zhang S. M., Hernan M. A., Schwarzschild M. A., Willett W. C., Colditz G. A., Speizer F. E. Ascherio A. (2003a) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60, 1059 1064.
12. Chen J., Li Y., Katakowski M., Chen X., Wang L., Lu D., Lu M., Gautam S. C. Chopp M. (2003b) Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J. Neurosci. Res. 73, 778 786.
13. Chung E. S., Joe E. H., Ryu J. K. et al. (2001) GT1b ganglioside induces death of dopaminergic neurons in rat mesencephalic cultures. Neuroreport 12, 611 614.
14. Du Y., Ma Z., Lin S. et al. (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl Acad. Sci. USA 98, 14669 14674.
15. Emborg M. E. (2004) Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J. Neurosci. Methods 139, 121 143.
16. Hattori N. Mizuno Y. (2004) Pathogenetic mechanisms of parkin in Parkinson's disease. Lancet 364, 722 724.
17. He Y., Appel S. Le W. (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 909, 187 193.
18. Healy D. G., Abou-Sleiman P. M. Wood N. W. (2004) PINK, PANK, or PARK? A clinicians' guide to familial parkinsonism. Lancet Neurol. 3, 652 662.
19. Hellmann M. A., Panet H., Barhum Y., Melamed E. Offen D. (2006) Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci. Lett. 395, 124 128.
20. Hernandez T. D. Schallert T. (1988) Seizures and recovery from experimental brain damage. Exp. Neurol. 102, 318 324.
21. Jankowski K., Kucia M., Wysoczynski M. et al. (2003) Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res. 63, 7926 7935.
22. Kirik D., Rosenblad C. Bjorklund A. (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152, 259 277.
23. Kordower J. H., Kanaan N. M., Chu Y., Suresh Babu R., Stansell J. III., Terpstra B. T., Sortwell C. E., Steece-Collier K. Collier T. J. (2006) Failure of proteasome inhibitors to provide a model of Parkinson's disease in rats and monkeys. Ann. Neurol. 60, 264 268.
24. Lee P. H., Kim J. W., Bang O. Y., Ahn Y. H., Joo I. S. Huh K. (2007) Autologous Mesenchymal Stem Cell Therapy Delays the Progression of Neurological Deficits in Patients With Multiple System Atrophy. Clin. Pharmacol. Ther. doi :.
25. Li Y., Chen J., Wang L., Zhang L., Lu M. Chopp M. (2001) Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson's disease. Neurosci. Lett. 316, 67 70.
26. Liu M., Guo Y. M., Yang J. L., Wang P., Zhao L. Y., Shen N., Wang S. C., Guo X. J. Wu Q. F. (2006) Application of cell penetrating peptide in magnetic resonance imaging of bone marrow mesenchymal stem cells. Acta Biochim Biophys Sin 38, 865 873.
27. Makino S., Fukuda K., Miyoshi S. et al. (1999) Cardiomyocytes can be generated from marrow stromal cells in vitro. J. Clin. Invest. 103, 697 705.
28. Manning-Bog A. B., Reaney S. H., Chou V. P., Johnston L. C., McCormack A. L., Johnston J., Langston J. W. Di Monte D. A. (2006) Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann. Neurol. 60, 256 260.
29. Mareschi K., Novara M., Rustichelli D. et al. (2006) Neural differentiation of human mesenchymal stem cells: Evidence for expression of neural markers and eag K+ channel types. Exp. Hematol. 34, 1563 1572.
30. Mazzini L., Fagioli F., Boccaletti R., Mareschi K., Oliveri G., Olivieri C., Pastore I., Marasso R. Madon E. (2003) Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph Lateral Scler Other Motor Neuron Disord 4, 158 161.
31. McNaught K. S., Perl D. P., Brownell A. L. Olanow C. W. (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56, 149 162.
32. Moore D. J., West A. B., Dawson V. L. Dawson T. M. (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57 87.
33. Morris H. R. (2005) Genetics of Parkinson's disease. Ann. Med. 37, 86 96.
34. Offen D., Barhum Y., Levy Y. S., Burshtein A., Panet H., Cherlow T. Melamed E. (2007) Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease. J. Neural Transm. Suppl. 72, 133 143.
35. Olanow C. W. McNaught K. S. (2006) Ubiquitin-proteasome system and Parkinson's disease. Mov. Disord. 21, 1806 1823.
36. Park H. J., Lee P. H., Ahn Y. W., Choi Y. J., Lee G., Lee D. Y., Chung E. S. Jin B. K. (2007) Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur. J. Neurosci. 26, 79 89.
37. Pittenger M. F., Mackay A. M., Beck S. C. et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284, 143 147.
38. Reaney S. H., Johnston L. C., Langston W. J. Di Monte D. A. (2006) Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures. Exp. Neurol. 202, 434 440.
39. Rideout H. J. Stefanis L. (2002) Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol. Cell. Neurosci. 21, 223 238.
40. Sairam K., Saravanan K. S., Banerjee R. Mohanakumar K. P. (2003) Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res. 966, 245 252.
41. Schapira A. H., Cleeter M. W., Muddle J. R., Workman J. M., Cooper J. M. King R. H. (2006) Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann. Neurol. 60, 253 255.
42. Schrag A. Schott J. M. (2006) Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 5, 355 363.
43. Stumm R. K., Rummel J., Junker V., Culmsee C., Pfeiffer M., Krieglstein J., Hollt V. Schulz S. (2002) A dual role for the SDF-1/CXCR4 chemokine receptor system in adult brain: isoform-selective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. J. Neurosci. 22, 5865 5878.
44. Tatton W. G., Chalmers-Redman R., Brown D. Tatton N. (2003) Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann. Neurol. 53 (Suppl. 3 S61 S70.
45. Teismann P., Tieu K., Choi D. K., Wu D. C., Naini A., Hunot S., Vila M., Jackson-Lewis V. Przedborski S. (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl Acad. Sci. USA 100, 5473 5478.
46. Watanabe E., Sudo R., Takahashi M. Hayashi M. (2000) Evaluation of absorbability of poorly water-soluble drugs: validity of the use of additives. Biol. Pharm. Bull. 23, 838 843.
47. West M. J., Slomianka L. Gundersen H. J. (1991) Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231, 482 497.
48. Woodbury D., Schwarz E. J., Prockop D. J. Black I. B. (2000) Adult rat and human bone marrow stromal cells differentiate into neurons. J. Neurosci. Res. 61, 364 370.
49. Ye M., Wang X. J., Zhang Y. H., Lu G. Q., Liang L., Xu J. Y. Sheng-Di C. (2007) Therapeutic effects of differentiated bone marrow stromal cell transplantation on rat models of Parkinson's disease. Parkinsonism Relat Disord. 13, 44 49.
50. Zeng B. Y., Bukhatwa S., Hikima A., Rose S. Jenner P. (2006) Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann. Neurol. 60, 248 252.